🇺🇸 FDA
Pipeline program

TN-401

TN-401-0012

Phase 1 gene_therapy active

Quick answer

TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy is a Phase 1 program (gene_therapy) at Tenaya Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Tenaya Therapeutics
Indication
Arrhythmogenic Right Ventricular Cardiomyopathy
Phase
Phase 1
Modality
gene_therapy
Status
active

Clinical trials